Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orbcel C - Orbsen Therapeutics

Next Previous
Search
Drug Profile

Orbcel C - Orbsen Therapeutics

Alternative Names: Allogeneic umbilical cord-derived mesenchymal stromal cell therapy - Orbsen Therapeutics; Human umbilical cord derived CD362 enriched MSCs; ORBCEL C™; Orbcel-C

Latest Information Update: 12 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orbsen Therapeutics
  • Developer Belfast Health and Social Care Trust; University of Birmingham
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Autoimmune hepatitis; Primary sclerosing cholangitis
  • Phase I/II Adult respiratory distress syndrome

Most Recent Events

  • 05 Jun 2024 Efficacy and adverse event data from a phase II trial in Autoimmune hepatitis and Primary sclerosing cholangitis presented at European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 24 Jan 2023 Allogeneic umbilical cord-derived mesenchymal stromal cell therapy is still in phase I/II clinical trial in Adult respiratory distress syndrome (In adults, In adolescents, In the elderly) in United Kingdom
  • 24 Jan 2023 Allogeneic umbilical cord-derived mesenchymal stromal cell therapy is still in phase II clinical trial in Autoimmune hepatitis and Primary sclerosing cholangitis in United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top